January 2025

Contents

Editorial

• Looking back through 2024 and forward to 2025…

• i-Base appeal: Q&A services and the website in 2025

Special reports

• Almost 1 in 5 people in Switzerland disconnected from HIV care over 10 years: only half reconnected and with advanced infection

• ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir

Antiretrovirals

• EU license for injectable cabotegravir/rilpivirine injections expanded to include adolescents >12 years old

• Transient impact of lenacapavir against MDR HIV-2 without other active ART

• Lenacapavir submitted to the US FDA with an indication for HIV PrEP

Treatment access

• US issues temporary waiver to re-enable PEPFAR

• IAS statement: PEPFAR freeze threatens millions of lives

• Trump bans travel for US government scientists, presentations restricted, language bans, documents disappearing

Pregnancy

• BHIVA pregnancy guidelines online for comment: deadline 25 January

mpox

• Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox clade 1

• Tecovirimat news continues: Japan approval includes mpox indication